Our Services

Colorectal Carcinoma (CRC)

Colorectal cancer is the third most common type of cancer in men and women in the United States. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer.

A Novel Drug, Regorafenib, for the Treatment of Stage IIIB or IIIC Colorectal Cancer that Has Been Previously Treated Clinical Trial

  • Study name: "ARGO"
  • Stage IIIB or IIIC
  • Patients are randomized, in a double-blind fashion, to treatment arms in a 1:1 ratio: Regorafenib or placebo
  • Patients must have had an en bloc complete gross resection of their tumor and completed standard of care chemotherapy
  • Main study doctor (Principal Investigator): Thomas Stanton, MD
  • For more information, please contact the lead coordinator, Kimberly Young, at 707-521-3814 or at Kimberly.Young@stjoe.org

Immunotherapy or Chemotherapy for Microsatellite instability high (MSI-H) or MMR deficient (dMMR) Colorectal Cancer Clinical Trial

  • Study name: “Keynote 177”
  • Patients must be newly diagnosed with stage IV colorectal carcinoma (CRC) and have not received treatment for stage IV CRC
  • All patients receive treatment
  • Patients are randomized to treatment arms in a 1:1 ratio: Pembrolizumab (Keytruda) vs. the physician’s choice of standard of care (SOC) chemotherapy
  • Patients need to be Microsatellite instability high (MSI-H) or MMR deficient (dMMR)
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

Novel STAT3 Inhibitor for Colorectal Cancer Refractory to First Line FOLFOX or XELOX Plus Bevacizumab Using Clinical Trial

  • Study name: CanStem303C
  • Stage IV
  • Patients must have Progressed on at least 6 weeks of first line FOLFOX or XELOX with bevacizumab
  • No more than 2 prior uses of systemic treatment
  • Patients are randomized to treatment arms in a 1:1 ratio: BBI-608 + FOLFIRI ± bevacizumab vs. FOLFIRI ± bevacizumab
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org